Skip to content
PubMed This is a summary of 56 peer-reviewed journal articles Updated
Nephrology

Fanconi renotubular syndrome 3 (FRTS3): A Patient Guide

At a Glance

FRTS3 is a rare genetic kidney disorder in which the kidney’s recycling tubes lose phosphate and bicarbonate into urine. Because the gene change cannot currently be repaired, individualized supplements and regular blood and urine tests help protect bone and kidney health.

Fanconi renotubular syndrome 3 (FRTS3) is an exceptionally rare genetic condition that fundamentally changes how the kidneys manage the body’s essential nutrients. Because the evidence is limited to a very small number of reported families, treatment decisions must be highly individualized. Unlike many kidney diseases that involve a failure to filter the blood, FRTS3 is a disorder of the “recycling” system located in the proximal tubules [1][2].

In a healthy kidney, these tubules act as a sophisticated reclamation center, pulling vital substances like sugar, phosphate, and bicarbonate back into the bloodstream before they can be lost in the urine. In people with FRTS3, a pathogenic variant in the EHHADH gene disrupts the energy production within these tubule cells, leaving them without the power they need to perform this critical recycling work [3][4].

When this reclamation process fails, the body begins to “waste” essential building blocks into the urine. This loss of nutrients—particularly phosphate and bicarbonate—can lead to significant challenges for bone health and the body’s overall acid-base balance [5]. Over time, the chronic loss of phosphate may cause bones to soften or weaken, a condition known as rickets in children or osteomalacia in adults [2][6]. Because the kidneys are also losing water along with these nutrients, some individuals experience a constant, intense thirst and a frequent need to urinate [7].

One of the most striking features of FRTS3 is its profound variability. Even within the same family, where multiple people carry the exact same genetic variant, the condition can behave very differently [2]. One person might have severe symptoms that require several daily supplements, while a relative might have only minor lab abnormalities and no physical symptoms at all [4][8]. This unpredictability means that while some patients face earlier kidney impairment, others maintain stable health and good kidney function for many decades [2][9].

Because there is currently no way to repair the underlying genetic variant, management focuses on supportive care—the process of carefully replacing exactly what the kidneys are losing [10]. This journey requires a lifelong partnership with a specialized nephrology or metabolic-bone team. Regular blood and urine monitoring helps ensure the body’s mineral levels remain in a healthy range [11][12]. While living with a rare diagnosis brings unique challenges, a consistent, individualized management plan aims to reduce complications, protect bone health, and preserve kidney function [2].

Common questions in this guide

What is Fanconi renotubular syndrome 3 (FRTS3)?
FRTS3 is an exceptionally rare genetic kidney disorder caused by a disease-causing change in the EHHADH gene. It affects the proximal tubules, which normally reclaim nutrients and other substances from the fluid that becomes urine.
What symptoms can FRTS3 cause?
People with FRTS3 may have intense thirst and frequent urination, while some have only abnormal blood or urine results. Loss of phosphate can soften or weaken bones, causing rickets in children or osteomalacia in adults; fatigue or bone pain should also be discussed with a clinician.
How is FRTS3 diagnosed and monitored?
Evaluation may include biochemical blood and urine tests and genetic testing for an EHHADH variant. Ongoing blood and urine monitoring helps guide supplements and track mineral balance, bone health, and kidney function.
How is FRTS3 treated?
There is currently no way to repair the underlying EHHADH gene change. Treatment is supportive and individualized, usually replacing substances lost in the urine with supplements and using regular blood and urine tests to adjust care.
Does everyone with FRTS3 develop kidney failure?
No. FRTS3 can vary greatly, even among relatives with the same genetic variant: some people develop earlier kidney impairment, while others keep stable kidney function for many decades. Regular follow-up helps clinicians identify changes and protect kidney health.
Should family members be tested for FRTS3?
Because FRTS3 is genetic and can occur in multiple members of a family, relatives may benefit from discussing testing with the care team. Clinicians can recommend which relatives to evaluate and whether genetic testing, blood or urine testing, or both are appropriate.

Get notified when new evidence is published on Fanconi renotubular syndrome 3.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (12)
  1. 1

    Proximal renal tubular acidosis with and without Fanconi syndrome.

    Kashoor I, Batlle D

    Kidney research and clinical practice 2019; (38(3)):267-281 doi:10.23876/j.krcp.19.056.

    PMID: 31474092
  2. 2

    A puzzling renal Fanconi syndrome.

    Haydock L, Hureaux M, Hoffmann M, et al.

    Clinical kidney journal 2025; (18(8)):sfae408 doi:10.1093/ckj/sfae408.

    PMID: 40800210
  3. 3

    Renal Fanconi Syndrome Is Caused by a Mistargeting-Based Mitochondriopathy.

    Assmann N, Dettmer K, Simbuerger JMB, et al.

    Cell reports 2016; (15(7)):1423-1429 doi:10.1016/j.celrep.2016.04.037.

    PMID: 27160910
  4. 4

    The recurrent p.Glu3Lys variant in EHHADH is responsible for Fanconi syndrome with early liver dysfunction and mitochondrial abnormalities.

    Rollier P, Cospain A, Barth M, et al.

    Molecular genetics and metabolism reports 2025; (43()):101214 doi:10.1016/j.ymgmr.2025.101214.

    PMID: 40242153
  5. 5

    Fanconi Syndrome.

    Foreman JW

    Pediatric clinics of North America 2019; (66(1)):159-167 doi:10.1016/j.pcl.2018.09.002.

    PMID: 30454741
  6. 6

    [GENETIC DISORDERS OF RENAL PHOSPHATE HANDLING].

    Magen D

    Harefuah 2017; (156(10)):654-658.

    PMID: 29072386
  7. 7

    A case of ifosfamide-induced acute kidney injury, Fanconi syndrome, and nephrogenic diabetes insipidus.

    Hoang S, Pujar T, Bellorin-Font E, et al.

    CEN case reports 2024; (13(3)):194-198 doi:10.1007/s13730-023-00829-z.

    PMID: 37897631
  8. 8

    Unveiling long-standing low-molecular-weight proteinuria: A proximal tubular mitochondrial enzyme impairment caused by EHHADH mutation.

    Tanaka H, Imasawa T, Tsugawa K, et al.

    Pediatric nephrology (Berlin, Germany) 2026; (41(3)):675-678 doi:10.1007/s00467-025-07020-9.

    PMID: 41117969
  9. 9

    Inherited Fanconi renotubular syndromes: unveiling the intricacies of hypophosphatemic rickets/osteomalacia.

    Ragate DC, Memon SS, Karlekar M, et al.

    Journal of bone and mineral metabolism 2024; (42(2)):155-165 doi:10.1007/s00774-023-01490-3.

    PMID: 38310177
  10. 10

    Renal Tubular Acidosis.

    Bagga A, Sinha A

    Indian journal of pediatrics 2020; (87(9)):733-744 doi:10.1007/s12098-020-03318-8.

    PMID: 32591997
  11. 11

    Management of bone disease in cystinosis: Statement from an international conference.

    Hohenfellner K, Rauch F, Ariceta G, et al.

    Journal of inherited metabolic disease 2019; (42(5)):1019-1029 doi:10.1002/jimd.12134.

    PMID: 31177550
  12. 12

    Rickets guidance: part II-management.

    Haffner D, Leifheit-Nestler M, Grund A, Schnabel D

    Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.

    PMID: 35352187

This page is for informational purposes only and does not constitute medical advice. FRTS3 treatment is individualized, so discuss genetic testing, supplements, and monitoring with your nephrologist or metabolic-bone specialist.